Literature DB >> 35990187

Management of combined hepatocellular carcinoma-cholangiocarcinoma.

Ju Dong Yang1, Lewis R Roberts1.   

Abstract

Purpose of Review: To review the recent consensus on the nomenclature, clinical features, diagnosis, and treatment of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Recent finding: cHCC-CCA is a primary liver carcinoma with varying degrees of hepatocytic and cholangiocytic cytology and architecture within the same tumor. The diagnosis of cHCC-CCA can only be established based on histologic examination. Surgical resection should be considered in patients with resectable tumors who do not have underlying liver disease or clinically significant portal hypertension. While treatment by liver transplantation (LT) is controversial due to the high risk of post LT recurrence, LT should remain as a potentially curative option in a highly selected group of patients. Little data exist for the outcome of other treatments. Summary: High quality multicenter prospective studies should be conducted to better understand this rare, but increasingly recognized tumor.

Entities:  

Keywords:  biphenotypic tumor; hepatocellular cholangiocarcinoma; hepatocholangiocarcinoma; mixed tumor; treatment

Year:  2018        PMID: 35990187      PMCID: PMC9387765          DOI: 10.1007/s11901-018-0431-9

Source DB:  PubMed          Journal:  Curr Hepatol Rep        ISSN: 2195-9595


  40 in total

Review 1.  Morphologic Subtypes of Hepatocellular Carcinoma.

Authors:  Michael S Torbenson
Journal:  Gastroenterol Clin North Am       Date:  2017-06       Impact factor: 3.806

2.  Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.

Authors:  G Sapisochin; M Facciuto; L Rubbia-Brandt; J Marti; N Mehta; F Y Yao; E Vibert; D Cherqui; D R Grant; R Hernandez-Alejandro; C H Dale; A Cucchetti; A Pinna; S Hwang; S G Lee; V G Agopian; R W Busuttil; S Rizvi; J K Heimbach; M Montenovo; J Reyes; M Cesaretti; O Soubrane; T Reichman; J Seal; P T W Kim; G Klintmalm; C Sposito; V Mazzaferro; P Dutkowski; P A Clavien; C Toso; P Majno; N Kneteman; C Saunders; J Bruix
Journal:  Hepatology       Date:  2016-08-24       Impact factor: 17.425

3.  Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Authors:  Jane E Rogers; Ryan M Bolonesi; Asif Rashid; Khaled M Elsayes; Mohamed G Elbanan; Lindsey Law; Ahmed Kaseb; Rachna T Shroff
Journal:  J Gastrointest Oncol       Date:  2017-04

4.  Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center.

Authors:  Qian Zhan; Bai-Yong Shen; Xia-Xing Deng; Zhe-Cheng Zhu; Hao Chen; Chen-Hong Peng; Hong-Wei Li
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-07       Impact factor: 7.027

5.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Young-In Yoon; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jong-Woo Lee; Seung-Mo Hong; Eun Sil Yu; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-12-01       Impact factor: 3.452

6.  Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.

Authors:  William R Jarnagin; Sharon Weber; Satish K Tickoo; Jonathan B Koea; Sam Obiekwe; Yuman Fong; Ronald P DeMatteo; Leslie H Blumgart; David Klimstra
Journal:  Cancer       Date:  2002-04-01       Impact factor: 6.860

7.  Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.

Authors:  Jun Akiba; Osamu Nakashima; Satoshi Hattori; Ken Tanikawa; Miki Takenaka; Masamich Nakayama; Reiichiro Kondo; Yoriko Nomura; Keiko Koura; Kousuke Ueda; Sakiko Sanada; Yoshiki Naito; Rin Yamaguchi; Hirohisa Yano
Journal:  Am J Surg Pathol       Date:  2013-04       Impact factor: 6.394

8.  Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Ki Hun Kim; Sung Gyu Lee; Eun Hwa Park; Shin Hwang; Chul Soo Ahn; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Kang Mo Kim; Young Suk Lim; Han Chu Lee; Young Hwa Chung; Yung Sang Lee; Dong Jin Suh
Journal:  Ann Surg Oncol       Date:  2009-01-06       Impact factor: 5.344

9.  Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics.

Authors:  John R Bergquist; Ryan T Groeschl; Tommy Ivanics; Christopher R Shubert; Elizabeth B Habermann; Michael L Kendrick; Michael B Farnell; David M Nagorney; Mark J Truty; Rory L Smoot
Journal:  HPB (Oxford)       Date:  2016-08-18       Impact factor: 3.647

10.  Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.

Authors:  Maëva Salimon; Caroline Prieux-Klotz; David Tougeron; Vincent Hautefeuille; Morgane Caulet; Jérôme Gournay; Tamara Matysiak-Budnik; Jaafar Bennouna; Manuela Tiako Meyo; Thierry Lecomte; Aziz Zaanan; Yann Touchefeu
Journal:  Br J Cancer       Date:  2017-11-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.